We believe that TLR4-IN-C34 is a novel therapeutic strategy that decreases ISO-related AKI by modulating TLR4/NF-κB/MAPK/MYD88 signaling thereby attenuating inflammation, oxidative stress, and apoptosis. This evidence concerns the gene MYD88 and acute kidney injury.